Tag: covid

In a group of hospitalized COVID-19 patients, a therapeutic dose of low-molecular-weight heparin reduced major thromboembolic events and death. Evidence Rating Level: 1 (Excellent) Thrombotic events such as a deep vein thrombosis and pulmonary embolisms are common in patients hospitalized with COVID-19. Severely ill patients with COVID-19 often experience thrombosis despite...
1. Immune-mediated inflammatory disease patients treated with tumor necrosis factor (TNF) inhibitor were associated with fewer hospitalizations or deaths due to COVID-19 than those treated with only methotrexate, with only azathioprine/6-mercaptopurine, with TNF inhibitor and azathioprine/6-mercaptopurine, or with only a Jak inhibitor. Evidence Rating Level: 3 (Average) Study Rundown: Treatment of...
Methylprednisolone therapy in nonintubated patients with COVID-19 receiving high-flow oxygen therapy was associated with clinical benefit solely in patients with baseline serum ferritin levels in the upper tertile of values. In contrast, for patients with ferritin in the lower and middle tertiles, no association with benefit...
1. Mortality rate increased from 36.9% to 51.9% from early 2020 (before May 1) to late 2020 (after May 2) for COVID-19 patients treated with ECMO. 2. Experienced centers in delivering ECMO had an almost 50% reduced mortality rate compared to inexperienced centers. Evidence Rating Level: 2 (Good) Study Rundown: ECMO (Extracorporeal...
1. Individuals not immune to COVID-19 had at least a 45% decreased risk of COVID-19 infection if at least one family member was immune (through previous infection or two vaccine doses). Evidence Rating Level: 2 (Good) Study Rundown: SARS-CoV-2 is predominantly transmitted through person-to-person contact, rendering the spread of this virus...
1. In children and adolescents, meeting the 60 min/day physical activity recommendation and having less screen time were associated with fewer mental health difficulties. 2. More mental health difficulties in children and adolescents were detected during this survey conducted during the SARS-CoV2 (COVID-19) pandemic than pre-pandemic studies. Evidence Rating Level: 3...
1. Methylprednisolone therapy in nonintubated patients with COVID-19 receiving high-flow oxygen therapy was associated with clinical benefit solely in patients with baseline serum ferritin levels in the upper tertile of values. 2. In contrast, for patients with ferritin in the lower and middle tertiles, no association with benefit was observed. Evidence...
1. The primary outcome of mortality or dependency was greater in patients with VITT-associated CVT compared to non-VITT CVT (p=0.0061). 2. Better prognosis was seen in VITT-associated CVT for patients treated with non-heparin anticoagulants (p=0.0031) and intravenous immunoglobulins (p=0.022). Evidence Rating Level: 2 (Good) Study Rundown: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is...
1. An interval of 44-45 weeks between the first and second dose resulted in a four-fold increase in median antibody titers, 28-days after administration, compared to the standard interval of 8-12 weeks. 2. A two-fold increase in median IgG levels was observed among patients 28-days after receiving their third dose...
1. Heterologous AstraZeneca followed by Pfizer vaccination was noninferior to homologous, two-dose AstraZeneca vaccination with a geometric mean ratio of 9.2. 2. Heterologous Pfizer followed by AstraZeneca vaccination was not found to be non-inferior to homologous, two-dose Pfizer vaccination. Evidence Rating Level: 1 (Excellent) Study Rundown: Heterologous prime-boost vaccination schedules involve administering...